Shots:
- Meitheal Pharmaceuticals & its parent, Hong Kong King-Friend Industry (HKF), have entered into an exclusive licensing agreement for commercializing biosimilars of pegfilgrastim & filgrastim in oncology and follitropin alpha for fertility treatment in the US
- Pegfilgrastim (SC, once per cycle) & filgrastim (SC, IV, daily for 14 days in CT treatment cycle) are bone marrow stimulants which enhance WBC production in cancer patients by binding to G-CSF receptors, stimulating neutrophil proliferation & activation against infection
- Follitropin alpha is a recombinant human follicle-stimulating hormone (FSH) used to promote follicle development in women & spermatogenesis in men during fertility treatments
Ref: Meitheal Pharmaceuticals | Image: Meitheal Pharmaceuticals | Press Release
Related News:- Alvotech and Teva Reports the US FDA’s Approval for the Additional Presentation of Selarsdi (Biosimilar, Stelara)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
